Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017168 (
gastroesophageal reflux disease
)
11,783
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Medical treatment is effective in the majority of patients with
gastroesophageal reflux disease
(
GERD
). Lifestyle modifications are often recommended for patients with
GERD
, although the data supporting lifestyle recommendations are limited. Antacids are often used to treat the symptoms of
GERD
, but their effect is short-lived. H2-receptor antagonists and proton-pump inhibitors provide more effective options for remission of
GERD
symptoms and healing of esophagitis. Prokinetic medications (e.g., metoclopramide) have not been proven to help in the control of symptoms.
Baclofen
, which inhibits transient lower esophageal sphincter relaxations, provide an additional option for patients with persistent symptoms related to
GERD
; however its use is limited by side effects. Long-term medical therapy for
GERD
should be tailored to each patient to provide symptomatic control and maintain esophageal mucosal healing.
...
PMID:Medical Treatment of Gastroesophageal Reflux Disease. 2832 55
Baclofen
has been shown to decrease reflux events and increase lower esophageal sphincter pressure, yet has never established a clear role in the treatment of
gastroesophageal reflux disease
(
GERD
). Lei and colleagues have shown in a recent elegant study that baclofen reduces the frequency and initiation of secondary peristalsis and heightens esophageal sensitivity to capsaicin-mediated stimulation. These findings may help explain both the benefit of baclofen in conditions such as rumination and supragastric belching, as well as the apparent lack of benefit of baclofen and other GABA
B
agonists in long-term treatment of
GERD
.
...
PMID:Baclofen and gastroesophageal reflux disease: seeing the forest through the trees. 2898 Oct 81
Rumination syndrome is a functional gastrointestinal disorder characterized by effortless postprandial regurgitation. The disorder appears uncommon, although only limited epidemiologic data are available. Awareness of the characteristic symptoms is essential for recognizing the disorder, and thus avoiding the long delay in diagnosis, that many patients experience. Although objective testing by postprandial esophageal high-resolution impedance manometry is available in select referral centers, a clinical diagnosis can be made in most patients. The main therapy for rumination syndrome is behavioral modification with postprandial diaphragmatic breathing. This clinical practice update reviews the pathophysiology, diagnosis, and treatment of rumination syndrome. Best Practice Advice 1: Clinicians strongly should consider rumination syndrome in patients who report consistent postprandial regurgitation. Such patients often are labeled as having refractory
gastroesophageal reflux
or vomiting. Best Practice Advice 2: Presence of nocturnal regurgitation, dysphagia, nausea, or symptoms occurring in the absence of meals does not exclude rumination syndrome, but makes the presence of it less likely. Best Practice Advice 3: Clinicians should diagnose rumination syndrome primarily on the basis of Rome IV criteria after an appropriate medical work-up. Best Practice Advice 4: Diaphragmatic breathing with or without biofeedback is the first-line therapy in all cases of rumination syndrome. Best Practice Advice 5: Instructions for effective diaphragmatic breathing can be given by speech therapists, psychologists, gastroenterologists, and other health practitioners familiar with the technique. Best Practice Advice 6: Objective testing for rumination syndrome with postprandial high-resolution esophageal impedance manometry can be used to support the diagnosis, but expertise and lack of standardized protocols are current limitations. Best Practice Advice 7:
Baclofen
, at a dose of 10 mg 3 times daily, is a reasonable next step in refractory patients.
...
PMID:Diagnosis and Treatment of Rumination Syndrome. 2990 42
Pharmacologic therapy, surgery, minimally invasive therapies, and alternative therapies are different options available for the management of refractory
GERD
. The choice may depend on the cause of refractoriness. Increased gastric acid suppression therapy might be useful in the rare patients with persistent elevated esophageal acid exposure on proton pump inhibitors (PPI). Potassium-competitive acid blockers (P-CAB) might induce a more important acid inhibition than PPI.
Baclofen
might act as a reflux inhibitor and demonstrates a significant efficacy in rumination syndrome. The role of topical antacid-alginate in refractory
GERD
might be limited. Surgery might be a valid option in case of persistent pathological acid esophageal exposure despite PPI. Further evaluation of minimally invasive procedures is necessary. Finally diet, diaphragmatic breathing and transcutaneous electrical acustimulation might be of interest in patients with esophageal hypersensivity or functional symptoms.
...
PMID:Refractory GERD, beyond proton pump inhibitors. 3024 Sep 68
This is the first case report describing a laparoscopic fundoplication in a child with an intrathecal
Baclofen
pump which was inserted because of severe spasticity secondary to cerebral palsy. The child had symptoms of
gastroesophageal reflux
with recurrent episodes of aspiration pneumonia. These were managed with a gastrostomy and conservative therapy with no success. The presence of an intrathecal
Baclofen
pump makes abdominal surgery challenging and carries the risk of pump infection with its associated sequelae. However, we performed a successful laparoscopic fundoplication with no intraoperative complications and the child was asymptomatic at 18 months follow-up.
...
PMID:Laparoscopic fundoplication for a child with abdominal intrathecal Baclofen pump. 3143 37
<< Previous
1
2
3